drug
iloprost
Marketedupdated 3mo agoby BTG International Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4all catalysts(1)
Trials studying iloprost
- phase3Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
- phase2Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)
- phase3The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
- phase3Iloprost Power 15 in Pulmonary Arterial Hypertension
- —Ventavis® Registry Protocol
- —Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)
- phase3Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure
- phase4Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 13, 2027
179 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Jul 18, 2044method-of-use (U-4263)US 12409183
- Aug 6, 2041formulationUS 12409184
FDA exclusivities (2)
- Feb 13, 2031ODE-465Orphan Drug (7y)4.5y
- Feb 13, 2027NPNP179d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 5m ago
Found something off?
comments(0)
5-min edit window · permanent after that